Auxano Advisors LLC Has $2.49 Million Position in Johnson & Johnson (NYSE:JNJ)

Auxano Advisors LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 5.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 15,005 shares of the company’s stock after selling 843 shares during the quarter. Johnson & Johnson comprises 0.7% of Auxano Advisors LLC’s holdings, making the stock its 25th biggest position. Auxano Advisors LLC’s holdings in Johnson & Johnson were worth $2,488,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. MRP Capital Investments LLC boosted its position in shares of Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock valued at $237,000 after acquiring an additional 65 shares during the period. Syverson Strege & Co boosted its position in shares of Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock valued at $202,000 after acquiring an additional 65 shares during the period. MBA Advisors LLC boosted its position in shares of Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock valued at $921,000 after acquiring an additional 68 shares during the period. Sovereign Financial Group Inc. boosted its position in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after acquiring an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc boosted its position in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after acquiring an additional 69 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE JNJ opened at $163.65 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a market cap of $393.75 billion, a price-to-earnings ratio of 17.50, a PEG ratio of 2.18 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a 50-day moving average price of $154.29 and a two-hundred day moving average price of $154.97.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.82 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.18%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on JNJ. UBS Group reissued a “buy” rating and issued a $190.00 target price (up previously from $180.00) on shares of Johnson & Johnson in a research report on Thursday. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Morgan Stanley boosted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday. Finally, Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $172.87.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.